WOLF SIEGMUND
No ORCID on file
· 60 papers in corpus
· active 2011
Frequent coauthors
- BRUDER SANDRA 60
- OTTO CHRISTIANE 60
- TRAUTWEIN MARK 60
- FREIBERG CHRISTOPH 60
- GREVEN SIMONE 60
- HARRENGA AXEL 60
- EICKER ANDREA 30
- WILMEN ANDREAS 30
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…